Trevena

Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), announced key data today from two separate preclinical studies. The data provides fascinating insights into the potential effects of TRV045, a novel S1P1 …

Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management Read More



NRx Pharmaceuticals